Human Monoclonal Antibodies Could Be Beneficial to Address Intractable Diseases

Identification of fully ‘human monoclonal antibodies’ against the intractable disease targets will be the main objective of a new research collaboration between ”Genmab” and “Pepscan Therapeutics”, the companies from Denmark and Netherland respectively.

Present technological set up has its own limitations with such identification and it has become more urgent to device new techniques to address the issue. It could be mainly due to the fact that the target proteins are deposited in a large quantity near the cell surface or within the cell membrane. There may be other reasons as well like the poor immunogenicity of the protein or the epitopes that are required.

Both the companies feel that the collaboration would facilitate detailed evaluation of the disease targets and it will help in addressing and evolving new standard treatments.

Monoclonal Antibodies against intractable targets are a significant unmet need. A combination of ‘Pepscan CLIPS protein mimicry platform’ and the ‘Genmab’s ability to generate fully ‘human monoclonal’ will enable the partners to develop innovative products for poorly served indications.

Monoclonal antibodies and intractable disease are not the most edge of you seat topics, but the collaboration between “Pepscan Therapeutics” and “Genmab” makes using the antibodies to target intractable disease an ever improving scientific method.

Monoclonal antibodies are identical as a result of their being produced by one type of immune cell that was developed from one single originating cell. Their ability to target specific problems within the body gave people hope for a magic bullet type cure.

The possibility became higher in the year 1988 when the antibodies were produced successfully in the laboratory for the first time. This extraordinary human achievement led to almost complete reduction in allergic reactions to the foreign antibodies being introduced into human beings.

Intractable diseases, which cause chronic pain and even death in those that suffer from the various diseases, are a perfect candidate for the monoclonal antibodies. Intractable diseases, those that can’t be treated easily by standard methods, would be great targets for antibodies developed to attack the types of cells causing a particular problem.

One of the most common applications of this science is in the treatment of cancer cells. By developing antibodies that can differentiate between the healthy cell and the cancerous cell, the antibodies can be introduced with a fair amount of success, while the cancer cells are being destroyed there is little or no allergic reaction because the antibodies virtually ignore the other, healthy cells.

The main focus of the collaboration is bringing together the ‘CLIPS technology’ that the Pepscan Company has developed with the antibodies that Genmab develops. The ‘CLIPS technology’ will be used to develop copies of the essential proteins of intractable diseases. By combining the two technologies the companies hope to develop new antibodies that will target diseases that currently receive treatment at a very low or non-existent success rate.

This article is the property of http://www.HealthHype.com
Copying and publishing any article from our site is strictly NOT allowed